Super Group (SGHC) Limited has spent the week consolidating the post-earnings short build, with borrowed positions stabilising at elevated levels even as the stock climbs and analysts revise higher.
The most striking development in positioning is not a new move — it's the absence of one. Short interest peaked near 21.3 million shares on May 11, immediately after the Q1 earnings print, and has barely shifted since. As noted in the May 13 trader note, that post-earnings build represented a 50% jump from pre-results levels. A week on, shorts have neither added meaningfully nor covered — the position is sitting at 21.1 million shares, down just 1.3% on the week. That patience is notable given the stock has gained another 7.4% this week to $13.87, extending the monthly gain to 23%. Shorts are underwater on those positions and have not flinched.
The lending market, however, is sending an increasingly relaxed signal. Availability has loosened sharply — from a tightest reading of 77% on May 7, when the lending pool was most constrained, to 266% now. More shares are available to borrow relative to what is already out on loan than at any point in the past two weeks. Cost to borrow remains trivial at 0.51% annualised, barely moved on the week. The short score has also eased from a week-high of 67.2 on May 11 to 60.4 today, drifting back toward where it was before the earnings-driven spike. Borrow conditions are not tightening into the short position — if anything, the pool is opening up.
Options positioning adds a new wrinkle this week. The put/call ratio has jumped to 0.095, more than two standard deviations above its 20-day average of 0.044. That is the most defensive options reading for SGHC in recent months, even though in absolute terms a PCR of 0.095 is still low. The contrast with earlier weeks is sharp: through April and into early May the PCR barely exceeded 0.04, with calls dominating. The shift toward puts — though modest in absolute terms — aligns with a stock that has rallied 23% in a month and where some holders are buying downside protection into that extended run.
The Street remains constructive and is moving targets higher. Citizens raised its target to $17 from $16 on May 20, maintaining its Market Outperform rating. That follows Macquarie lifting its target to $19 from $18 on May 13 after the earnings print. Both moves are consistent with the bullish consensus: every analyst covering SGHC carries a buy-equivalent rating, and the mean price target of $18.13 implies roughly 31% upside from current levels. The EPS momentum score of 79 and earnings surprise rank of 70 support that optimism — the company has a track record of beating estimates. The valuation, however, has re-rated: the P/E has expanded by 1.6 points over the past 30 days to 16.8x, and price-to-book has risen by more than 1 turn to 5.9x. The stock is no longer cheap by its own recent standards.
On the institutional side, one new entry stands out. Helikon Investments initiated a position of 9.4 million shares in Q1, reported as a full new build. Invesco added 1.8 million shares in the same period. The two dominant holders — Alea Trust at 44.6% and Chivers Trust at 19.3% — trimmed marginally but remain overwhelmingly dominant in the register. On the insider side, CEO Neal Menashe and CFO Alinda Van Wyk both sold in early April at $10.71 — well below the current price — following a tranche of awards at end-March. HR Director Kirsty Farrah Ross sold again last week at $13.03. The sales follow award grants and do not represent a new bearish signal, but the cadence of executive selling into the rally is worth tracking.
The next scheduled earnings event is August 6. Between now and then, the key tension is whether the 21-million-share short position — built aggressively around the May print and held through a further 7% move higher — eventually covers and adds fuel to the rally, or whether the bears prove right that the valuation re-rating has run its course.
See the live data behind this article on ORTEX.
Open SGHC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
